PDF-RegenerativeEndodonticTreatment(Revascularization)forNecroticImmatureP

FromtheDepartmentofEndodonticsSchoolofDentistryRafsanjanUniversityofMedicalSciencesRafsanjanKermanDepartmentofOralBiologySchoolofDentistryUniver CaseReportClinicalTechniquesNosratetalVolume. A new treatment option of revasculariza tion has recently been introduced It involves disinfecting the root canal system providing a matrix of blood clot into which cells could grow and sealing of the coronal access The present pilot clinical study subacutely. or chronically occluded vessel ?. Feasible and I believe relatively safe considering the disease state and options we are up against but there have been complications…. Bilateral Vertebral Occlusion with Reperfusion Injury. . c. oronary. . d. isease. . d. iagnosed. . at the . t. ime. . of . p. rimary. . PCI for STEMI: . c. omplete. . r. evascularization. . v. ersus. . c. onservative. . s. trategy. . . PRAGUE . Sergio . Leonardi. , L. Kristin Newby, E. Magnus . Ohman. , Paul W. Armstrong.. November 16. th. 2010. . Chicago, IL – AHA Scientific Sessions. Disclosures Information. None of the authors have relevant financial disclosures. e. valuation of routine follow-up coronary. A. ngiography after percutaneous . C. oronary intervention . T. rial (. ReACT. ). Hiroki Shiomi, MD. Kyoto University Graduate School of Medicine. Percutaneous. Coronary Interventions in . Washington State. Chris L. Bryson, MD, MS, COAP Medical Director. Steven M. Bradley, MD; Charles Maynard, PhD. VA Puget Sound Healthcare System and University of Washington. vs. FFR-guided . Coronary Intervention . –. . iFR. -SWEDEHEART. Matthias Götberg, . MD, . PhD. Department of Cardiology, Lund University. Skane. University Hospital. Lund, Sweden. Disclosures. Volcano/Philips: Unrestricted grant to fund . The REAL-CAD Study in 13,054 Patients . With Stable Coronary Artery Disease . Disclosure: Public Health Research Foundation, Kowa Pharmaceutical Co. Ltd.. Takeshi Kimura, Teruo Inoue, Isao Taguchi, Hiroshi Iwata, Satoshi Iimuro, . Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation. C. linical . O. utcomes . U. tilizing . R. evascularization and . Ag(?). gressive. Drug . E. valuation. In patients with STABLE coronary artery disease (CAD), what treatment should I pursue initially?. COURAGE By Sukrit Narula Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation C linical O utcomes U tilizing R evascularization and Ag(?) gressive Drug E valuation In patients with STABLE coronary artery disease (CAD), what treatment should I pursue initially? . Mark Nidorf, Aernoud Fiolet, Arend Mosterd, John Eikelboom, . Astrid Schut, Charley Budgeon, Jan Tijssen, Jan Hein Cornel, Peter Thompson. and the LoDoCo2 Investigators .  . Mark Nidorf has no declaration of interest . S. Elissa Altin, MD. Assistant Professor . Yale University. VA Connecticut. Disclosures. I have no disclosures.. Learning Objectives. Prevalence of angina in women. Prevalence of non-obstructive disease in women. iFR-Swedeheart. 5-year outcome. Matthias Götberg, MD, PhD. Skane. University Hospital, Lund University, Sweden. - on behalf of the . iFR-Swedeheart. investigators. Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.. on behalf of the OPTIMUM Investigators. O. utcomes of . P. ercutaneous . Revasculariza. TI. on. for . M. anagement of . S. U. rgically. Ineligible Patients with . M. ultivessel or Left Main Coronary Artery Disease: Primary Results from the .